Weekly Analysts’ Ratings Changes for Cooper Companies (COO)

Several analysts have recently updated their ratings and price targets for Cooper Companies (NASDAQ: COO):

• 3/13/2025 – Cooper Companies was upgraded by analysts at BNP Paribas to a “hold” rating.
• 3/7/2025 – Cooper Companies had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $115.00 price target on the stock, down previously from $120.00.
• 3/7/2025 – Cooper Companies had its price target lowered by analysts at JPMorgan Chase & Co. from $120.00 to $110.00. They now have an “overweight” rating on the stock.
• 3/7/2025 – Cooper Companies had its price target lowered by analysts at Robert W. Baird from $117.00 to $107.00. They now have an “outperform” rating on the stock.
• 3/7/2025 – Cooper Companies had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 3/7/2025 – Cooper Companies had its price target lowered by analysts at Stifel Nicolaus from $115.00 to $105.00. They now have a “buy” rating on the stock.
• 3/7/2025 – Cooper Companies had its price target lowered by analysts at Citigroup Inc. from $115.00 to $110.00. They now have a “buy” rating on the stock.

Cooper Companies Trading Up 0.2 %

Shares of COO stock opened at $83.86 on Thursday. The business has a 50-day moving average price of $89.66 and a two-hundred day moving average price of $97.62. The Cooper Companies, Inc. has a 12-month low of $77.05 and a 12-month high of $112.38. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The firm has a market cap of $16.77 billion, a P/E ratio of 43.01, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Institutional Trading of Cooper Companies

Institutional investors have recently added to or reduced their stakes in the business. Byrne Asset Management LLC bought a new stake in shares of Cooper Companies in the 4th quarter valued at about $33,000. OFI Invest Asset Management purchased a new position in Cooper Companies in the 4th quarter worth approximately $34,000. New Age Alpha Advisors LLC bought a new stake in Cooper Companies in the fourth quarter valued at approximately $38,000. Covestor Ltd boosted its stake in shares of Cooper Companies by 35.5% during the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock valued at $42,000 after purchasing an additional 120 shares during the period. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after purchasing an additional 275 shares during the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.